Abbott's Xience V stent marks steady share gains: Abbott's Xience V everolimus-eluting coronary stent is "on track to exit 2007 with overall market share in the mid- to high-20% range" outside the United States, the firm reports during its July 18 earnings call. In India, market share is over 30%. The device debuted internationally last October and Abbott continues to expect U.S. approval in the first half of 2008; the firm completed its PMA filing in late May. Abbott's drug-eluting stent franchise generated $60 million in sales in Q2. The latter figure is roughly equal to the first quarter level because a 40% sequential increase in Xience sales was offset by lower "third party-related DES revenues," the firm explains. Overall Abbott Vascular sales, including stents, were up 63% year-over-year to $423 million in Q2 - reflecting Abbott's acquisition of Xience developer Guidant Vascular in April 2006. Leading a 20% advance in Abbott's medical product sales for the quarter, the Vascular segment remains on target for 60% growth for the full year, Abbott notes...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.
Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.
Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.
